Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 99

Results For "RSE"

1530 News Found

Biologicals have emerged as a therapy of choice where traditional chemical drugs fail: Dr Bharati Pravin Pawar
Policy | July 01, 2022

Biologicals have emerged as a therapy of choice where traditional chemical drugs fail: Dr Bharati Pravin Pawar

National Institute of Biologicals should undertake the testing of more biologicals and also extend its testing expertise in helping other countries


NADMED brings first CE-marked NAD+ analysis kit to the market
Medical Device | June 30, 2022

NADMED brings first CE-marked NAD+ analysis kit to the market

NADMED technology is based on proprietary extraction and the individual measurement of NAD metabolites


Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3
News | June 29, 2022

Novartis data show nearly 80% of RMS patients treated with ofatumumab had no evidence of NEDA-3

Earlier initiation with Kesimpta resulted in a more than three-fold increased likelihood of maintaining NEDA-3 throughout the study


Apollo Education UK launches the Apollo International Clinical Fellowship Programme
News | June 29, 2022

Apollo Education UK launches the Apollo International Clinical Fellowship Programme

Doctors will study for a Master of Surgery or Master of Medicine degree at Edge Hill University.


Pharma industry warming up towards adoption of digital technologies
Digitisation | June 27, 2022

Pharma industry warming up towards adoption of digital technologies

By applying digital technologies, pharma companies can significantly improve their operational and decision-making capabilities


Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease
Drug Approval | June 27, 2022

Astellas’s update on the Fortis clinical trial of AT845 in adults for pompe disease

The FDA informed Astellas that it did not have sufficient information to assess the risks to subjects


Novartis commits US$ 250 million to the fight against NTDs and malaria
Public Health | June 24, 2022

Novartis commits US$ 250 million to the fight against NTDs and malaria

This includes USD 100 million to advance R&D of its neglected tropical disease program, focusing on novel drug candidates for four diseases.


Rivaroxaban approved in Japan for patients with PAD after revascularisation
Drug Approval | June 24, 2022

Rivaroxaban approved in Japan for patients with PAD after revascularisation

It´s the first trial to demonstrate the benefits of dual pathway inhibition


Indian Pharma Post organizes e-Conference on ‘Role of Digitalization in Pharma Sector’  June 24
Digitisation | June 23, 2022

Indian Pharma Post organizes e-Conference on ‘Role of Digitalization in Pharma Sector’ June 24

Sanjay Verma of Akums Drugs & Pharmaceuticals, Manu Gupta of Cadila Pharmaceuticals, Rahul Borse of RPG Life Sciences, Krishna Sai T of Biocon and Amit Saluja of NASSCOM are speakers


Unilever, Genomatica form venture to develop palm oil based alternatives
News | June 20, 2022

Unilever, Genomatica form venture to develop palm oil based alternatives

With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology